vs
Side-by-side financial comparison of Pasithea Therapeutics Corp. (KTTA) and RenovoRx, Inc. (RNXT). Click either name above to swap in a different company.
Pasithea Therapeutics Corp. is the larger business by last-quarter revenue ($240.7K vs $238.0K, roughly 1.0× RenovoRx, Inc.). RenovoRx, Inc. runs the higher net margin — -1235.7% vs -2126.1%, a 890.3% gap on every dollar of revenue.
Pasithea Therapeutics Corp. is a clinical-stage biopharmaceutical firm dedicated to developing novel treatments for psychiatric and neurological conditions including treatment-resistant mood disorders. It primarily operates in North American and European markets, targeting patient segments that lack effective existing treatment options.
RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapy delivery systems for cancer treatment. Its core assets include proprietary transarterial delivery platforms, with primary operations in the United States, serving unmet medical needs in the oncology care segment.
KTTA vs RNXT — Head-to-Head
Income Statement — Q4 FY2022 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $240.7K | $238.0K |
| Net Profit | $-5.1M | $-2.9M |
| Gross Margin | — | 88.2% |
| Operating Margin | -1679.5% | -1479.8% |
| Net Margin | -2126.1% | -1235.7% |
| Revenue YoY | — | — |
| Net Profit YoY | — | -2.2% |
| EPS (diluted) | $-1.72 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $238.0K | ||
| Q3 25 | — | $266.0K | ||
| Q2 25 | — | $422.0K | ||
| Q1 25 | — | $197.0K | ||
| Q4 22 | $240.7K | — | ||
| Q3 22 | $218.6K | — | ||
| Q2 22 | $13.6K | — | ||
| Q1 22 | $13.7K | $1.0K |
| Q4 25 | — | $-2.9M | ||
| Q3 25 | — | $-2.9M | ||
| Q2 25 | — | $-2.9M | ||
| Q1 25 | — | $-2.4M | ||
| Q4 22 | $-5.1M | — | ||
| Q3 22 | $-4.6M | — | ||
| Q2 22 | $-2.7M | — | ||
| Q1 22 | $-1.6M | $-3.0M |
| Q4 25 | — | 88.2% | ||
| Q3 25 | — | 80.1% | ||
| Q2 25 | — | 64.0% | ||
| Q1 25 | — | 52.3% | ||
| Q4 22 | — | — | ||
| Q3 22 | 60.4% | — | ||
| Q2 22 | — | — | ||
| Q1 22 | 5.3% | — |
| Q4 25 | — | -1479.8% | ||
| Q3 25 | — | -1203.0% | ||
| Q2 25 | — | -634.6% | ||
| Q1 25 | — | -1578.7% | ||
| Q4 22 | -1679.5% | — | ||
| Q3 22 | -1763.8% | — | ||
| Q2 22 | -19229.5% | — | ||
| Q1 22 | -15221.0% | -300500.0% |
| Q4 25 | — | -1235.7% | ||
| Q3 25 | — | -1094.7% | ||
| Q2 25 | — | -686.0% | ||
| Q1 25 | — | -1228.4% | ||
| Q4 22 | -2126.1% | — | ||
| Q3 22 | -2097.9% | — | ||
| Q2 22 | -19574.4% | — | ||
| Q1 22 | -11526.1% | -300300.0% |
| Q4 25 | — | $-0.08 | ||
| Q3 25 | — | $-0.08 | ||
| Q2 25 | — | $-0.08 | ||
| Q1 25 | — | $-0.08 | ||
| Q4 22 | $-1.72 | — | ||
| Q3 22 | $-0.01 | — | ||
| Q2 22 | $-0.02 | — | ||
| Q1 22 | $-0.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $33.1M | $7.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $42.5M | $5.4M |
| Total Assets | $45.2M | $8.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $7.0M | ||
| Q3 25 | — | $10.0M | ||
| Q2 25 | — | $12.3M | ||
| Q1 25 | — | $14.6M | ||
| Q4 22 | $33.1M | — | ||
| Q3 22 | $42.4M | — | ||
| Q2 22 | $47.9M | — | ||
| Q1 22 | $50.3M | $13.1M |
| Q4 25 | — | $5.4M | ||
| Q3 25 | — | $8.1M | ||
| Q2 25 | — | $10.6M | ||
| Q1 25 | — | $13.2M | ||
| Q4 22 | $42.5M | — | ||
| Q3 22 | $46.8M | — | ||
| Q2 22 | $51.3M | — | ||
| Q1 22 | $50.0M | $12.5M |
| Q4 25 | — | $8.1M | ||
| Q3 25 | — | $11.2M | ||
| Q2 25 | — | $13.6M | ||
| Q1 25 | — | $16.0M | ||
| Q4 22 | $45.2M | — | ||
| Q3 22 | $49.6M | — | ||
| Q2 22 | $53.0M | — | ||
| Q1 22 | $51.1M | $13.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.4M | $-3.0M |
| Free Cash FlowOCF − Capex | $-4.5M | — |
| FCF MarginFCF / Revenue | -1874.2% | — |
| Capex IntensityCapex / Revenue | 38.5% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-14.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-3.0M | ||
| Q3 25 | — | $-2.3M | ||
| Q2 25 | — | $-2.3M | ||
| Q1 25 | — | $-3.4M | ||
| Q4 22 | $-4.4M | — | ||
| Q3 22 | $-5.2M | — | ||
| Q2 22 | $-2.4M | — | ||
| Q1 22 | $-2.5M | $-2.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-3.4M | ||
| Q4 22 | $-4.5M | — | ||
| Q3 22 | $-5.2M | — | ||
| Q2 22 | $-2.4M | — | ||
| Q1 22 | $-2.5M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -1717.3% | ||
| Q4 22 | -1874.2% | — | ||
| Q3 22 | -2398.9% | — | ||
| Q2 22 | -17553.7% | — | ||
| Q1 22 | -18519.8% | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 1.0% | ||
| Q4 22 | 38.5% | — | ||
| Q3 22 | 2.5% | — | ||
| Q2 22 | 51.1% | — | ||
| Q1 22 | 14.3% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
